PMID- 27043920
OWN - NLM
STAT- MEDLINE
DCOM- 20170413
LR  - 20220408
IS  - 1420-908X (Electronic)
IS  - 1023-3830 (Linking)
VI  - 65
IP  - 8
DP  - 2016 Aug
TI  - Inhibitory effect of baicalin on allergic response in ovalbumin-induced allergic 
      rhinitis guinea pigs and lipopolysaccharide-stimulated human mast cells.
PG  - 603-12
LID - 10.1007/s00011-016-0943-0 [doi]
AB  - OBJECTIVE: Baicalin, a flavonoid compound purified from the dry roots of 
      Scutellaria baicalensis Georgi, has generally been used for the treatment of 
      various allergic diseases. However, there is little information about the 
      anti-inflammatory effects of baicalin for allergic rhinitis. This study aims to 
      investigate the anti-allergic effect of baicalin on allergic response in 
      ovalbumin (OVA)-induced allergic rhinitis guinea pigs and lipopolysaccharide 
      (LPS)-stimulated human mast cells. METHODS: Using in vivo models, we evaluated 
      the effect of baicalin on allergic rhinitis symptoms via recording the number of 
      nasal rubs and sneezes. The levels of histamine, OVA-specific immunoglobulin 
      E(IgE), eosinophil cationic protein (ECP) and inflammatory cytokines were 
      measured using enzyme-linked immunosorbent assay (ELISA). The histological 
      changes of nasal mucosa were observed by light microscope after HE staining. In 
      vitro, the release of histamine and beta-hexosaminidase of compound 48/80-induced 
      human mast cells were measured by ELISA and PNP-NAG colorimetry, respectively. 
      The productions of inflammatory cytokines of LPS-stimulated human mast cells were 
      determined using ELISA. Western blot was used to test the protein expression of 
      JAK2, p-JAK2, STAT5, p-STAT5, IKKbeta, p-IKKbeta, IkappaBalpha, p-IkappaBalpha and NF-kappaB (p65) of 
      LPS-stimulated human mast cells. RESULTS: The oral administration of baicalin at 
      doses of 50 and 200 mg/kg improved allergic rhinitis symptoms and the 
      histological changes of nasal mucosa and decreased the serum levels of histamine, 
      ECP, interleukin (IL)-1beta, IL-6, IL-8, tumor necrosis factor (TNF)-alpha and 
      OVA-specific IgE in OVA-induced allergic rhinitis guinea pigs. In vitro, baicalin 
      suppressed the release of histamine and beta-hexosaminidase in compound 
      48/80-induced human mast cells. In addition, baicalin also inhibited the 
      productions of inflammatory cytokines such as IL-1beta, IL-6, IL-8 and TNF-alpha and 
      suppressed the phosphorylation of JAK2, STAT5, IKKbeta, IkappaBalpha and the nuclear 
      translocation of NF-kappaB (p65) subunit in LPS-stimulated human mast cells. 
      CONCLUSIONS: These results suggest that baicalin can effectively prevent allergic 
      response in OVA-induced allergic rhinitis guinea pigs and inhibit inflammatory 
      response via blocking JAK2-STAT5 and NF-kappaB signaling pathways in LPS-stimulated 
      human mast cells. Considered together,the results show that baicalin may be a 
      useful drug in the treatment of allergic rhinitis.
FAU - Zhou, Yun-Jiang
AU  - Zhou YJ
AD  - Department of Pharmacology, Chongqing Medical University, Chongqing, 400016, 
      China.
AD  - Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, 
      400016, China.
FAU - Wang, Hu
AU  - Wang H
AD  - Department of Pharmacology, Chongqing Medical University, Chongqing, 400016, 
      China.
FAU - Sui, He-Huan
AU  - Sui HH
AD  - Department of Pharmacology, Chongqing Medical University, Chongqing, 400016, 
      China.
FAU - Li, Li
AU  - Li L
AD  - Department of Pharmacology, Chongqing Medical University, Chongqing, 400016, 
      China.
FAU - Zhou, Chun-Ling
AU  - Zhou CL
AD  - Jingzhou Institute of Technology, Jingzhou, 434020, Hubei, China.
FAU - Huang, Jia-Jun
AU  - Huang JJ
AD  - Department of Pharmacology, Chongqing Medical University, Chongqing, 400016, 
      China. huangjiajuncqmu@163.com.
AD  - Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, 
      400016, China. huangjiajuncqmu@163.com.
LA  - eng
PT  - Journal Article
DEP - 20160404
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Cytokines)
RN  - 0 (Flavonoids)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (STAT5 Transcription Factor)
RN  - 347Q89U4M5 (baicalin)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
RN  - EC 2.7.10.2 (Janus Kinase 2)
SB  - IM
MH  - Animals
MH  - Anti-Allergic Agents/pharmacology/*therapeutic use
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Cytokines/blood
MH  - Flavonoids/pharmacology/*therapeutic use
MH  - Guinea Pigs
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Janus Kinase 2/metabolism
MH  - Lipopolysaccharides
MH  - Male
MH  - Mast Cells/drug effects/immunology/metabolism
MH  - NF-kappa B/metabolism
MH  - Nasal Mucosa/drug effects/immunology
MH  - Ovalbumin
MH  - Rhinitis, Allergic/blood/*drug therapy/immunology
MH  - STAT5 Transcription Factor/metabolism
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - Baicalin
OT  - Human mast cells
OT  - Lipopolysaccharide
OT  - Ovalbumin
EDAT- 2016/04/05 06:00
MHDA- 2017/04/14 06:00
CRDT- 2016/04/05 06:00
PHST- 2015/11/17 00:00 [received]
PHST- 2016/03/25 00:00 [accepted]
PHST- 2016/03/23 00:00 [revised]
PHST- 2016/04/05 06:00 [entrez]
PHST- 2016/04/05 06:00 [pubmed]
PHST- 2017/04/14 06:00 [medline]
AID - 10.1007/s00011-016-0943-0 [pii]
AID - 10.1007/s00011-016-0943-0 [doi]
PST - ppublish
SO  - Inflamm Res. 2016 Aug;65(8):603-12. doi: 10.1007/s00011-016-0943-0. Epub 2016 Apr 
      4.